Navigation Links
BD Visitec Nasal Catheters

ProductsBD Visitec Nasal Catheters
Company BD Ophthalmics
Item BD Visitec Nasal Catheters
Features 
Description Designed for use in traditional external approach DCRs in pediatric patients & for endoscopic DCRs in adults or children. Lumen 6.0mm long, ID-1.4mm (.12 in); OD-5.0mm (.20 in), Outer flanges 8.0mm diameter; .50mm thick
Info BD Ophthalmics
Customer Service: (800) 237-2174
Web site: http://www.bd.com/ophthalmology

Related medicine products :

1. BD Visitec IOL Manipulator (Jaffe-Maltzman)
2. BD Visitec IOL Manipulator (Lester)
3. BD Visitec IOL Manipulator (Sinskey)
4. BD Visitec™ button tip manipulator
5. BD Visitec IOL Manipulator (Fenzl)
6. BD Visitec IOL Manipulator
7. BD Visitec Capsule Polishers
8. BD Visitec Iris Retractors
9. BD Visitec Irrigation and Aspiration Cannulas
10. BD Visitec J Shape Cannulas
11. BD Visitec Cortex Extractors
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 1Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 2Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 3Anxious Kids at Risk for Obesity in Adulthood 57251 1Anxious Kids at Risk for Obesity in Adulthood 57251 2The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2